235 related articles for article (PubMed ID: 18355682)
1. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.
Vāvere AL; Lewis JS
Nucl Med Biol; 2008 Apr; 35(3):273-9. PubMed ID: 18355682
[TBL] [Abstract][Full Text] [Related]
2. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
4. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
[TBL] [Abstract][Full Text] [Related]
5. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
6. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
7. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
8. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation.
Yoshii Y; Yoneda M; Ikawa M; Furukawa T; Kiyono Y; Mori T; Yoshii H; Oyama N; Okazawa H; Saga T; Fujibayashi Y
Nucl Med Biol; 2012 Feb; 39(2):177-85. PubMed ID: 22033022
[TBL] [Abstract][Full Text] [Related]
10. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.
Burgman P; O'Donoghue JA; Lewis JS; Welch MJ; Humm JL; Ling CC
Nucl Med Biol; 2005 Aug; 32(6):623-30. PubMed ID: 16026709
[TBL] [Abstract][Full Text] [Related]
11. Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.
Handley MG; Medina RA; Mariotti E; Kenny GD; Shaw KP; Yan R; Eykyn TR; Blower PJ; Southworth R
J Nucl Med; 2014 Mar; 55(3):488-94. PubMed ID: 24421288
[TBL] [Abstract][Full Text] [Related]
12. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.
Bonnitcha PD; Bayly SR; Theobald MB; Betts HM; Lewis JS; Dilworth JR
J Inorg Biochem; 2010 Feb; 104(2):126-35. PubMed ID: 19932509
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.
Clausen MM; Hansen AE; Af Rosenschold PM; Kjaer A; Kristensen AT; McEvoy FJ; Engelholm SA
Radiat Oncol; 2013 Nov; 8():262. PubMed ID: 24199939
[TBL] [Abstract][Full Text] [Related]
14. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
[TBL] [Abstract][Full Text] [Related]
15. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.
McQuade P; Martin KE; Castle TC; Went MJ; Blower PJ; Welch MJ; Lewis JS
Nucl Med Biol; 2005 Feb; 32(2):147-56. PubMed ID: 15721760
[TBL] [Abstract][Full Text] [Related]
16. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Liu J; Hajibeigi A; Ren G; Lin M; Siyambalapitiyage W; Liu Z; Simpson E; Parkey RW; Sun X; Oz OK
J Nucl Med; 2009 Aug; 50(8):1332-9. PubMed ID: 19617332
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging.
Jalilian AR; Rostampour N; Rowshanfarzad P; Shafaii K; Kamali-Dehghan M; Akhlaghi M
Acta Pharm; 2009 Mar; 59(1):45-55. PubMed ID: 19304557
[TBL] [Abstract][Full Text] [Related]
19. Basic characterization of 64Cu-ATSM as a radiotherapy agent.
Obata A; Kasamatsu S; Lewis JS; Furukawa T; Takamatsu S; Toyohara J; Asai T; Welch MJ; Adams SG; Saji H; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2005 Jan; 32(1):21-8. PubMed ID: 15691658
[TBL] [Abstract][Full Text] [Related]
20. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.
Clausen MM; Hansen AE; Lundemann M; Hollensen C; Pommer T; Munck Af Rosenschöld P; Kristensen AT; Kjær A; McEvoy FJ; Engelholm SA
Radiat Oncol; 2014 Oct; 9():228. PubMed ID: 25319766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
